EP1318797B1 - Volatile anaesthetic with xenon - Google Patents
Volatile anaesthetic with xenon Download PDFInfo
- Publication number
- EP1318797B1 EP1318797B1 EP01965268A EP01965268A EP1318797B1 EP 1318797 B1 EP1318797 B1 EP 1318797B1 EP 01965268 A EP01965268 A EP 01965268A EP 01965268 A EP01965268 A EP 01965268A EP 1318797 B1 EP1318797 B1 EP 1318797B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- xenon
- volume
- anesthetic
- vol
- volatile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
Definitions
- the invention relates to a volatile anesthetic containing xenon or used in combination with xenon.
- Volatile anesthetics include methoxyflurane, halothane, enflurane, isoflurane, sevoflurane and desflurane. Methoxyflurane is no longer used due to health risks.
- Xenon has been used as an inhalant anesthetic for many years. An overview of the anesthetic and pharmacological properties of xenon can be found in F. Giunta et al., "Xenon: a review of its anesthetic and pharmacological properties", Applied Cardiopulmonary Pathophysiology 00: 1-9, 1996 ,
- the so-called MAC value minimal alveolar concentration
- the MAC value is a guideline in anesthesia.
- the real required anesthetic agent concentration varies from patient to patient and depends on many parameters such as: a. age.
- the required anesthetic agent concentration therefore usually varies in the range of 0.7 to 1.3 times the value of the MAC.
- the human MAC value for xenon is 71% by volume xenon.
- the invention has for its object to provide an agent for anesthesia, which has fewer disadvantages.
- the anesthetic contains as one component xenon or a xenon-containing gas and, as further component, isoflurane, sevoflurane or desflurane as a volatile anesthetic, the components being used for simultaneous, separate or sequential use in anesthesia.
- the anesthetic agent preferably consists of xenon or a xenon-containing gas and a volatile anesthetic.
- the anesthetic which is particularly preferably used in the form of the separate components in a coordinated manner for anesthesia, is therefore also referred to as a combination anesthetic or as a combination inhalation anesthetic.
- the anesthetic or its components are gaseous in use.
- the combination content anesthetic is preferably prepared immediately prior to use by mixing the currently employed inhalant anesthetic agent components, oxygen, and optionally a gas, preferably a gas having inert properties (e.g., an inert gas), into a respirable gas.
- a gas preferably a gas having inert properties (e.g., an inert gas)
- Another object of the invention is the use of xenon and one or more volatile anesthetic agents as components for the preparation of a combination anesthetic for the separate or sequential use of the components in anesthesia.
- Another object of the invention is the use of xenon and a volatile anesthetic for the preparation of a combination anesthetic for simultaneous, separate or sequential use of the components in the anesthesia of patients with cardiopulmonary diseases or in operations with high blood loss.
- the combination anesthetic is used in humans or mammals.
- volatile anesthetic z. Halothane, enflurane, isoflurane, sevoflurane or desflurane.
- the volatile anesthetic component of the combination anesthetic may also be a mixture of two or more volatiles Be anesthetics. Preferred is the use of a single volatile anesthetic in the combination anesthetic.
- the anesthetic agent is preferably generated during use by adding xenon or a xenon-containing gas and a volatile anesthetic to a gas stream consisting of oxygen or containing sufficient oxygen for respiration.
- the metered addition of the anesthetic agent components takes place, for example, in a breathing tube of a patient.
- the generated gas mixture or combination anesthetic generally contains xenon in a concentration in the range of 10 to 80% by volume, preferably below the MAC value.
- the concentration of xenon is in the range from 10 to 65% by volume, preferably in the range from 30 to 65% by volume, more preferably in the range from 40 to 65% by volume, in particular in the range from 40 to 50% by volume .-%.
- the gas mixtures produced for anesthesia may contain, in addition to xenon and the volatile anesthetic, one or more gases or gaseous substances at body temperature and normal pressure.
- Additional gases include, for example, an inert gas such as nitrogen or noble gases (eg, helium, neon, argon, krypton).
- an inert gas such as nitrogen or noble gases (eg, helium, neon, argon, krypton).
- nitrogen or noble gases eg, helium, neon, argon, krypton.
- the admixture of one or more inert or inert behaving gases can be very advantageous when little xenon is to be brought into the body. This may be the case, for example, when anesthesia is stopped.
- the generated gas mixture or combination anesthetic preferably contains the volatile anesthetic in a concentration below the corresponding MAC, for example below 90% of the corresponding MAC, preferably below 75% of the corresponding MAC, more preferably below 50% corresponding MAC value, in particular below 25% of the corresponding MAC value.
- Isoflurane is preferred in patients with liver or kidney damage, preferably enflurane in patients with a heart condition or diseased heart, and in normal cases isoflurane, sevoflurane or desflurane is preferred to be volatile Anesthetic used in the combination anesthetic. Sevoflurane or desflurane is preferably used for a quick wake-up of the patient after anesthesia. In children, sevoflurane or halothane is preferably used as a volatile anesthetic in the combination anesthetic.
- the volatile anesthetics halothane, enflurane, isoflurane, sevoflurane or desflurane are preferably used in the following concentration ranges in the combination anesthetic or gas mixture in humans: from 0.2 to 0.75% by volume in halothane, from 0.6 to 1.6 vol from enflurane, from 0.5 to 1.15 vol.% for isoflurane, from 0.9 to 2.0 vol.% for sevoflurane and from 3.6 to 6.0 vol.% for desflurane (Values extrapolated from experiments with pigs).
- gas mixtures used consisting of 10 to 65 vol .-% xenon, a volatile anesthetic, oxygen and optionally one or more other gases, wherein the proportions of all components of the gas mixture together give 100 vol .-%.
- the oxygen content in the gas mixture is usually more than 20% by volume, preferably 30% by volume.
- oxygen concentrations of more than 40% by volume in the gas mixture (breathing gas) in particular by 50% by volume or more than 50% by volume, depending on the application, may be advantageous at times.
- a constantly increased oxygen concentration in the gas mixture is advantageous in particular for the anesthesia of patients with pulmonary diseases or in operations with a high blood loss.
- proportions of the gas components in the gas mixture produced during anesthesia are changed, that is, the anesthetic agent components or one of the anesthetic agent components are not kept constant or only temporarily constant.
- the proportions of anesthetic agent components are changed, for example individually or in pairs, stepwise or continuously.
- a component like xenon or volatiles Anesthetic can also be completely exposed for a period of time during anesthesia.
- gas mixtures concentration stages
- the gas mixtures are usually prepared in such a way that to a carrier gas stream of pure xenon, the volume fractions of the other components (eg of oxygen and a volatile anesthetic) are added.
- Gas metering is usually done with an anesthetic machine.
- Anesthesia is in many cases initiated with an injection anesthetic such as propofol and maintained with the combination inhalation anesthetic.
- a gas mixture of 70% by volume of xenon and 30% by volume of oxygen is administered at the beginning of the inhalation anesthesia.
- Table 1 Examples of xenon / isoflurane / oxygen gas mixtures (for human anesthesia)
- Range from / to Xenon / vol.% (Approximate value) 25 0/0 75 30 0/0 70 35 0 / 0.1 65 40 0.1 / 0.15 60 45 0.15 / 0.22 55 50 0.22 / 0.35 50 55 0.35 / 0.42 45 60 0.42 / 0.5 40 70 0.5 / 0.6 30 80 0.6 / 0.7 20 90 0.7 / 0.75 10
- various xenon concentrations can be adjusted by dosing an additional inert gas such as nitrogen, e.g. B. a gas mixture with 30 vol .-% oxygen, 60 vol .-% xenon, 1.2 vol .-% isoflurane and residual gas nitrogen.
- nitrogen e.g. B. a gas mixture with 30 vol .-% oxygen, 60 vol .-% xenon, 1.2 vol .-% isoflurane and residual gas nitrogen.
- the proportion of xenon and volatile anesthetic is sized so that the patient's blood pressure remains substantially constant during anesthesia or that critical blood pressure levels in a patient during anesthesia are avoided.
- xenon concentrations in the range of 30 to 55 vol.% In combination with 0.25 to 0.85 vol.% Isoflurane, 0.5 to 1.4 vol.% Enflurane, 1.0 to 4.0% by volume of desflurane, 0.9 to 1.8% by volume of sevoflurane or 0.15 to 0.6% by volume of halothane.
- xenon and a volatile anesthetic brings great benefits in anesthesia over the use of the single anesthetic.
- an oxygen content in the breathing gas of more than 29% by volume is possible (MAC of xenon at 71% in humans).
- Critical operations requiring higher oxygenation in human respiration are therefore possible, and the benefits of administering xenon are widely exploited.
- the volatile anesthetics are used in such quantities where the side effects of volatile anesthetic are no longer present in the known dimensions occur.
- the anesthetist in the combination anesthetic is given greater flexibility in controlling anesthesia.
- an additive anesthetic effect of inhaled xenon and isoflurane that allows the anesthesiologist to supplement anesthesia with xenon in a quick, easy, and inexpensive manner when there is a higher oxygen demand of the patient.
- a FiO 2 0.5 results in a xenon concentration of 50 vol .-%
- the MAC of isoflurane is reduced by about 30%. This allows a reduction in the dose of isoflurane, which reduces the side effects and leads to a safer anesthetic technique.
- the combined dosage of xenon and a volatile anesthetic for anesthesia is particularly beneficial in patients with cardiopulmonary disease and in operations with expected high blood loss.
- the xenon gas used generally has the natural isotopic composition.
- the isotopic composition of xenon may differ from the natural isotopic composition.
- the xenon gas is preferably used in high purity as usual for medical gases.
- the xenon gas serves as a pure gas or in admixture with other gases as a component of a combination inhalation anesthetic or combination inhalation anesthetic for simultaneous, separate or sequential use with the other anesthetic components in anesthesia.
- Gaseous xenon is generally provided as compressed, clean gas in pressurized gas containers such as compressed gas cylinders or pressure cans.
- Xenon can be provided in a container as a liquefied gas or in cold-strengthened form.
- Volatile anesthetics are generally provided as liquids.
- Volatile anesthetics and xenon are used as combination anesthetic agents, for example, with minimal flow anesthesia machines or so-called closed loop anesthesia machines, e.g. with the device "Physioflex” from Dräger (Lübeck, Germany) administered.
- Azerperon im (intramuscular) was 20 min. later a venous indwelling cannula placed in an ear vein. The induction of anesthesia took place with propofol in 2 mg / kg body weight. Intubation was performed without muscle relaxation using a 7.5 mm Woodbridge tube. In the further course, an arterial cannula was placed percutaneously in the artery of the ear for bloody blood pressure measurement and various blood collections. The anesthesia continued in this phase with boluses of 20 mg / kg bw propofol. The cumulative doses were between 170 and 500 mg (mean 276 mg).
- the animals were ventilated in a controlled manner so that the expiratory CO 2 was continuously between 40-45 mmHg. All animals were ventilated with an inspiratory / expiratory ratio of 1: 1 and a positive end-expiratory pressure (PEEP) of +3 cmH 2 O.
- the anesthesia device was a Dräger PhysioFlex.
- the body temperature was kept constant by means of a heating blanket (warm-touch, Mallinckrodt Medical, Ireland) at a temperature between 38.0 ° C and 39.5 ° C.
- MAP mean arterial blood pressure
- HR heart rate
- temperature were monitored continuously (AS / 3 compact, Datex-Engström, Heisinki / Finland). When applying the supramaximal stimulus, the current values were noted.
- the inhalation and expiratory concentration of halothane was monitored by infrared spectroscopy (AS / 3compact, Datex-Engstrom, Helsinki, Finland).
- the inspiratory xenon concentration was monitored by means of infrared spectroscopy using the PhysioFlex (Physio ä Dräger company, Lübeck Germany) , Due to the pharmacokinetic properties of the noble gas xenon, a very rapid equilibrium between inspiratory and expiratory concentration can be assumed, so that with a standard equilibration time of 20 min. It may be assumed that the concentration of inspiration and exhalation is identical.
- PaO 2 partial pressure of oxygen, tension in arterial blood
- PaCO 2 partial pressure of carbon dioxide, arterial blood
- pH sodium and potassium
- ABL 500 + EML 100, Radiometer Copenhagen , Danmark The urinary bladder was catheterized.
- a continuous infusion of an electrolyte solution of 0.1 ml / kg bw / min was started until the end of the experiment.
- anesthesia with halothane was continued until the propofol effect had no effect on the MAC value.
- the concentration of halothane was increased or decreased in steps of 0.1% by volume.
- the 10 animals were randomized to the two experimental groups. Group 1 started with xenon 0 vol% and descending halothane concentrations. The second group started with xenon 65% by volume and increasing concentrations.
- the trial protocol was started at the earliest 3 hours after premedication and 1 hour after the last propofol administration. As a result, influences of premedication and propofol administration could be ruled out.
- an equilibration time of at least 15 min. maintained and waited until steady state conditions had set. The measurements were carried out until a change in the response to the pain stimulus was recorded.
- a supramaximal pain stimulus was determined by the dew-claw-clamp method of Eger et al. (1988).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Die Erfindung betrifft ein volatiles Anästhesiemittel, das Xenon enthält oder in Kombination mit Xenon eingesetzt wird.The invention relates to a volatile anesthetic containing xenon or used in combination with xenon.
Zu den volatilen Anästhesiemitteln zählen Methoxyfluran, Halothan, Enfluran, Isofluran, Sevofluran und Desfluran. Methoxyfluran wird aufgrund gesundheitlicher Risiken nicht mehr eingesetzt.Volatile anesthetics include methoxyflurane, halothane, enflurane, isoflurane, sevoflurane and desflurane. Methoxyflurane is no longer used due to health risks.
Xenon wird schon seit vielen Jahren als Inhalationsanästhesiemittel eingesetzt. Eine Übersicht über die anästhetischen und pharmakologischen Eigenschaften des Xenon findet sich in
Als ein Maß der anästhetischen Potenz eines Anästhesiemittels wurde der sogenannte MAC-Wert (minimal alveolar concentration) eingeführt. Der MAC-Wert ist ein Richtwert in der Anästhesie. Die real erforderliche Anästhesiemittelkonzentration ist von Patient zu Patient verschieden und hängt von vielen Parametern wie u. a. dem Lebensalter ab. Die erforderliche Anästhesiemittelkonzentration schwankt daher gewöhnlich im Bereich des 0,7 bis 1,3 fachen Wertes des MAC-Wertes. Nach derzeitigem Kenntnisstand liegt der MAC-Wert beim Menschen für Xenon bei 71 Vol.-% Xenon.As a measure of the anesthetic potency of an anesthetic, the so-called MAC value (minimal alveolar concentration) was introduced. The MAC value is a guideline in anesthesia. The real required anesthetic agent concentration varies from patient to patient and depends on many parameters such as: a. age. The required anesthetic agent concentration therefore usually varies in the range of 0.7 to 1.3 times the value of the MAC. According to the current state of knowledge, the human MAC value for xenon is 71% by volume xenon.
Die bekannten volatilen Inhalationsanästhesiemittel haben eine Reihe von Nachteilen. So haben diese Mittel Blutdruck senkende Wirkung, werden im Körper nur allmählich abgebaut oder über Leber und Niere ausgeschieden und haben in der Regel unerwünschte Nebenwirkungen.The known volatile inhalation anesthetics have a number of disadvantages. Thus, these agents have blood pressure lowering effects, are only gradually degraded in the body or excreted via the liver and kidneys and usually have unwanted side effects.
Der Erfindung liegt die Aufgabe zugrunde, ein Mittel für die Anästhesie bereitzustellen, das weniger Nachteile aufweist.The invention has for its object to provide an agent for anesthesia, which has fewer disadvantages.
Überraschend wurde gefunden, daß bei einer Verabreichung von einem volatilen Anästhesiemittel mit gasförmigem Xenon die Nachteile bei dem Einsatz von volatilen Anästhesiemitteln deutlich verringert werden.Surprisingly, it has been found that the administration of a volatile anesthetic with gaseous xenon significantly reduces the disadvantages associated with the use of volatile anesthetics.
Gegenstand der Erfindung ist somit ein Anästhesiemittel mit den in Anspruch 1 beschriebenen Merkmalen sowie ein Gasgemisch nach den Ansprüchen 4 und 7.The invention thus an anesthetic with the features described in claim 1 and a gas mixture according to claims 4 and 7.
Das Anästhesiemittel enthält als eine Komponente Xenon oder ein xenonhaltiges Gas und als weitere Komponente Isofluran, Sevofluran oder Desfluran als ein volatiles Anästhesiemittel, wobei die Komponenten zur gleichzeitigen, getrennten oder zeitlich abgestuften Anwendung bei der Anästhesie eingesetzt werden. Das Anästhesiemittel besteht vorzugsweise aus Xenon oder einem xenonhaltigen Gas und einem volatilen Anästhesiemittel. Das Anästhesiemittel, das besonders bevorzugt in Form der getrennten Komponenten in abgestimmter Weise zur Anästhesie eingesetzt wird, wird daher auch als Kombinationsanästhesiemittel oder als Kombinationsinhalationsanästhesiemittel bezeichnet. Das Anästhesiemittel oder seine Komponenten sind bei Gebrauch gasförmig. Das Kombinationsinhaltionsanästhesiemittel wird vorzugsweise unmittelbar vor dem Gebrauch hergestellt, indem die aktuell einzusetzenden Inhalationsanästhesiemittelkomponenten, Sauerstoff und gegebenenfalls ein Gas, vorzugsweise ein Gas mit inerten Eigenschaften (z. B. ein Inertgas) zu einem atembaren Gas gemischt werden.The anesthetic contains as one component xenon or a xenon-containing gas and, as further component, isoflurane, sevoflurane or desflurane as a volatile anesthetic, the components being used for simultaneous, separate or sequential use in anesthesia. The anesthetic agent preferably consists of xenon or a xenon-containing gas and a volatile anesthetic. The anesthetic, which is particularly preferably used in the form of the separate components in a coordinated manner for anesthesia, is therefore also referred to as a combination anesthetic or as a combination inhalation anesthetic. The anesthetic or its components are gaseous in use. The combination content anesthetic is preferably prepared immediately prior to use by mixing the currently employed inhalant anesthetic agent components, oxygen, and optionally a gas, preferably a gas having inert properties (e.g., an inert gas), into a respirable gas.
Ein weiterer Gegenstand der Erfindung ist die Verwendung von Xenon und einem oder mehreren volatilen Anästhesiemitteln als Komponenten zur Herstellung eines Kombinationsanästhesiemittels zur getrennten oder zeitlich abgestuften Anwendung der Komponenten bei der Anästhesie. Ein weiterer Gegenstand der Erfindung ist die Verwendung von Xenon und einem volatilen Anästhesiemittel zur Herstellung eines Kombinationsanästhesiemittels zur gleichzeitigen, getrennten oder zeitlich abgestuften Anwendung der Komponenten bei der Anästhesie von Patienten mit cardiopulmonalen Erkrankungen oder bei Operationen mit hohem Blutverlust.Another object of the invention is the use of xenon and one or more volatile anesthetic agents as components for the preparation of a combination anesthetic for the separate or sequential use of the components in anesthesia. Another object of the invention is the use of xenon and a volatile anesthetic for the preparation of a combination anesthetic for simultaneous, separate or sequential use of the components in the anesthesia of patients with cardiopulmonary diseases or in operations with high blood loss.
Das Kombinationsanästhesiemittel wird beim Menschen oder bei Säugetieren eingesetzt.The combination anesthetic is used in humans or mammals.
Als volatiles Anästhesiemittel werden z. B. Halothan, Enfluran, Isofluran, Sevofluran oder Desfluran verwendet. Die Komponente des volatilen Anästhesiemittels bei dem Kombinationsanästhesiemittel kann auch ein Gemisch von zwei oder mehreren volatilen Anästhesiemitteln sein. Bevorzugt wird der Einsatz eines einzelnen volatilen Anästhesiemittels in dem Kombinationsanästhesiemittel.As a volatile anesthetic z. Halothane, enflurane, isoflurane, sevoflurane or desflurane. The volatile anesthetic component of the combination anesthetic may also be a mixture of two or more volatiles Be anesthetics. Preferred is the use of a single volatile anesthetic in the combination anesthetic.
Das Anästhesiemittel wird vorzugsweise während des Gebrauches durch Zudosierung von Xenon oder von einem xenonhaltigen Gas und einem volatilen Anästhesiemittel zu einem Gasstrom, der aus Sauerstoff besteht oder für die Atmung in ausreichender Menge Sauerstoff enthält, erzeugt. Die Zudosierung der Anästhesiemittelkomponenten erfolgt beispielsweise in einen Beatmungsschlauch eines Patienten. Das erzeugte Gasgemisch oder das Kombinationsanästhesiemittel enthalten Xenon im allgemeinen in einer Konzentration im Bereich von 10 bis 80 Vol.-%, vorzugsweise unterhalb des MAC-Wertes. Beispielsweise liegt die Konzentration von Xenon im Bereich von 10 bis 65 Vol.-%, vorzugsweise im Bereich von 30 bis 65 Vol.-%, besonders bevorzugt im Bereich von 40 bis 65 Vol.-%, insbesondere im Bereich von 40 bis 50 Vol.-%.The anesthetic agent is preferably generated during use by adding xenon or a xenon-containing gas and a volatile anesthetic to a gas stream consisting of oxygen or containing sufficient oxygen for respiration. The metered addition of the anesthetic agent components takes place, for example, in a breathing tube of a patient. The generated gas mixture or combination anesthetic generally contains xenon in a concentration in the range of 10 to 80% by volume, preferably below the MAC value. For example, the concentration of xenon is in the range from 10 to 65% by volume, preferably in the range from 30 to 65% by volume, more preferably in the range from 40 to 65% by volume, in particular in the range from 40 to 50% by volume .-%.
Die zur Anästhesie erzeugten Gasgemische können neben Xenon und dem volatilen Anästhesiemittel ein oder mehrere Gase oder bei Körpertemperatur und Normaldruck gasförmige Stoffe enthalten. Zusätzliche Gase sind beispielsweise ein Inertgas wie Stickstoff oder Edelgase (z. B. Helium, Neon, Argon, Krypton). Die Beimischung eines oder mehrerer inerter oder sich inert verhaltenden Gase kann sehr vorteilhaft sein, wenn wenig Xenon in den Körper gebracht werden soll. Dies kann zum Beispiel bei der Beendigung einer Narkose der Fall sein.The gas mixtures produced for anesthesia may contain, in addition to xenon and the volatile anesthetic, one or more gases or gaseous substances at body temperature and normal pressure. Additional gases include, for example, an inert gas such as nitrogen or noble gases (eg, helium, neon, argon, krypton). The admixture of one or more inert or inert behaving gases can be very advantageous when little xenon is to be brought into the body. This may be the case, for example, when anesthesia is stopped.
Das erzeugte Gasgemisch oder das Kombinationsanästhesiemittel enthalten das volatile Anästhesiemittel vorzugsweise in einer Konzentration unterhalb des entsprechenden MAC-Wertes, beispielsweise unterhalb von 90 % des entsprechenden MAC-Wertes, vorzugsweise unterhalb von 75 % des entsprechenden MAC-Wertes, besonders bevorzugt unterhalb von 50 % des entsprechenden MAC-Wertes, insbesondere unterhalb von 25 % des entsprechenden MAC-Wertes.The generated gas mixture or combination anesthetic preferably contains the volatile anesthetic in a concentration below the corresponding MAC, for example below 90% of the corresponding MAC, preferably below 75% of the corresponding MAC, more preferably below 50% corresponding MAC value, in particular below 25% of the corresponding MAC value.
Bei Patienten mit Leber- oder Nierenschäden wird vorzugsweise Isofluran, bei Patienten mit einem Herzleiden oder krankem Herzen wird vorzugsweise Enfluran und in normalen Fällen wird vorzugsweise Isofluran, Sevofluran oder Desfluran als volatiles Anästhesiemittel in dem Kombinationsanästhesiemittel eingesetzt. Für ein schnelles Aufwachen des Patienten nach der Narkose wird vorzugsweise Sevofluran oder Desfluran eingesetzt. Bei Kindern werden vorzugsweise Sevofluran oder Halothan als volatiles Anästhesiemittel in dem Kombinationsanästhesiemittel eingesetzt.Isoflurane is preferred in patients with liver or kidney damage, preferably enflurane in patients with a heart condition or diseased heart, and in normal cases isoflurane, sevoflurane or desflurane is preferred to be volatile Anesthetic used in the combination anesthetic. Sevoflurane or desflurane is preferably used for a quick wake-up of the patient after anesthesia. In children, sevoflurane or halothane is preferably used as a volatile anesthetic in the combination anesthetic.
Die volatilen Anästhesiemittel Halothan, Enfluran, Isofluran, Sevofluran oder Desfluran werden vorzugsweise in den folgenden Konzentrationsbereichen im Kombinationsanästhesiemittel oder Gasgemisch beim Menschen eingesetzt: von 0,2 bis 0,75 Vol.-% bei Halothan, von 0,6 bis 1,6 Vol.-% bei Enfluran, von 0,5 bis 1,15 Vol.-% bei Isofluran, von 0,9 bis 2,0 Vol.-% bei Sevofluran und von 3,6 bis 6,0 Vol.-% bei Desfluran (Werte extrapoliert von Versuchen mit Schweinen).The volatile anesthetics halothane, enflurane, isoflurane, sevoflurane or desflurane are preferably used in the following concentration ranges in the combination anesthetic or gas mixture in humans: from 0.2 to 0.75% by volume in halothane, from 0.6 to 1.6 vol from enflurane, from 0.5 to 1.15 vol.% for isoflurane, from 0.9 to 2.0 vol.% for sevoflurane and from 3.6 to 6.0 vol.% for desflurane (Values extrapolated from experiments with pigs).
Zur Anästhesie werden z. B. Gasgemische eingesetzt, bestehend aus 10 bis 65 Vol.-% Xenon, einem volatilen Anästhesiemittel, Sauerstoff und gegebenenfalls einem oder mehreren weiteren Gasen, wobei die Anteile aller Komponenten des Gasgemisches zusammen 100 Vol.-% ergeben. Der Sauerstoffgehalt in dem Gasgemisch beträgt in der Regel mehr als 20 Vol.-%, vorzugsweise um 30 Vol.-%. In besonderen Fällen, insbesondere in momentanen Notsituationen, können zeitweise Sauerstoffkonzentrationen von mehr als 40 Vol.-% im Gasgemisch (Atemgas), insbesondere um 50 Vol.-% oder mehr als 50 Vol.-%, je nach Anwendungsfall, vorteilhaft sein. Eine ständig erhöhte Sauerstoffkonzentration im Gasgemisch ist vorteilhaft insbesondere zur Anästhesie von Patienten mit pulmonalen Erkrankungen oder bei Operationen mit großem Blutverlust. In solchen Fällen werden beispielsweise Gasgemische mit Xenon und volatilem Anästhesiemittel mit einem Anteil von mindestens 30 Vol.-% Sauerstoff (FiO2 ≥ 0,3; FiO2 = fractional inspired oxygen tension) oder mindestens 50 Vol.-% Sauerstoff (FiO2 ≥ 0,5), je nach Anwendungsfall, eingesetzt.For anesthesia z. B. gas mixtures used, consisting of 10 to 65 vol .-% xenon, a volatile anesthetic, oxygen and optionally one or more other gases, wherein the proportions of all components of the gas mixture together give 100 vol .-%. The oxygen content in the gas mixture is usually more than 20% by volume, preferably 30% by volume. In special cases, in particular in current emergency situations, oxygen concentrations of more than 40% by volume in the gas mixture (breathing gas), in particular by 50% by volume or more than 50% by volume, depending on the application, may be advantageous at times. A constantly increased oxygen concentration in the gas mixture is advantageous in particular for the anesthesia of patients with pulmonary diseases or in operations with a high blood loss. In such cases, for example, gas mixtures with xenon and volatile anesthetic with a proportion of at least 30 vol .-% oxygen (FiO 2 ≥ 0.3, FiO 2 = fractional inspired oxygen tension) or at least 50 vol .-% oxygen (FiO 2 ≥ 0.5), depending on the application.
In der Regel werden Anteile der Gaskomponenten im erzeugten Gasgemisch während einer Narkose verändert, das heißt die Anästhesiemittelkomponenten oder eine der Anästhesiemittelkomponenten werden nicht konstant oder nur zeitweise konstant gehalten. Die Anteile der Anästhesiemittelkomponenten werden z.B. einzeln oder paarweise stufenweise oder stetig verändert. Eine Komponente wie Xenon oder volatiles Anästhesiemittel kann über ein Zeitintervall während der Narkose auch ganz ausgesetzt werden.In general, proportions of the gas components in the gas mixture produced during anesthesia are changed, that is, the anesthetic agent components or one of the anesthetic agent components are not kept constant or only temporarily constant. The proportions of anesthetic agent components are changed, for example individually or in pairs, stepwise or continuously. A component like xenon or volatiles Anesthetic can also be completely exposed for a period of time during anesthesia.
Beispiele von Gasgemischen (Konzentrationsstufen), zwischen denen in einer Narkose gewechselt werden kann (z.B. von einem Gasgemisch mit 30 Vol.-% Sauerstoff zu einem Gasgemisch mit 50 Vol.-% Sauerstoff), sind in den Tabellen 1 bis 5 aufgeführt. Die Gasgemische werden in der Regel in der Weise hergestellt, daß zu einem Trägergasstrom aus reinem Xenon die Volumenanteile der übrigen Komponenten (z.B. von Sauerstoff und einem volatilen Anästhesiemittel) zudosiert werden. Die Gasdosierung erfolgt in der Regel mit einem Anästhesiegerät. Eine Narkose wird in vielen Fällen mit einem Injektionsanästhesiemittel wie Propofol eingeleitet und mit dem Kombinationsinhalationsanästhesiemittel aufrechterhalten. Beispielsweise wird ein Gasgemisch aus 70 Vol.-% Xenon und 30 Vol.-% Sauerstoff zu Beginn der Inhalationsnarkose verabreicht. Bei höherer Sauerstoffdosierung wird z. B. auf eine andere Sauerstoffkonzentrationsstufe, wie in den Tabellen 1 bis 5 gezeigt, umgestellt, wobei die Narkosetiefe durch Veränderung der Konzentration des volatilen Anästhesiemittels in den aufgeführten Bereichen eingestellt wird. Im Verlauf der Narkose wird auf eine andere Sauerstoffkonzentrationsstufe oder die ursprüngliche Sauerstoffkonzentrationsstufe umgestellt.
Bei konstanter Sauerstoffkonzentration (z. B. 30 Vol.-% Sauerstoff) können verschiedene Xenonkonzentrationen durch Dosierung eines zusätzlichen Inertgases wie Stickstoff eingestellt werden, z. B. ein Gasgemisch mit 30 Vol.-% Sauerstoff, 60 Vol.-% Xenon, 1,2 Vol.-% Isofluran und restliches Gas Stickstoff.At constant oxygen concentration (eg, 30 vol% oxygen) various xenon concentrations can be adjusted by dosing an additional inert gas such as nitrogen, e.g. B. a gas mixture with 30 vol .-% oxygen, 60 vol .-% xenon, 1.2 vol .-% isoflurane and residual gas nitrogen.
Vorteilhaft wird in dem Kombinationsanästhesiemittel oder Gasgemisch der Anteil von Xenon und volatilem Anästhesiemittel so bemessen, daß der Blutdruck des Patienten während der Anästhesie im wesentlichen konstant bleibt oder daß kritische Blutdruckwerte bei einem Patienten während der Anästhesie vermieden werden.
Dies wird nach derzeitigem Kenntnisstand bei Xenon-Konzentrationen im Bereich von 30 bis 55 Vol.% in Kombination mit 0,25 bis 0,85 Vol.-% Isofluran, 0,5 bis 1,4 Vol.-% Enfluran, 1,0 bis 4,0 Vol.-% Desfluran, 0,9 bis 1,8 Vol.-% Sevofluran oder 0,15 bis 0,6 Vol.-% Halothan erreicht.Advantageously, in the combination anesthetic or gas mixture, the proportion of xenon and volatile anesthetic is sized so that the patient's blood pressure remains substantially constant during anesthesia or that critical blood pressure levels in a patient during anesthesia are avoided.
This, according to the current state of knowledge, is found at xenon concentrations in the range of 30 to 55 vol.% In combination with 0.25 to 0.85 vol.% Isoflurane, 0.5 to 1.4 vol.% Enflurane, 1.0 to 4.0% by volume of desflurane, 0.9 to 1.8% by volume of sevoflurane or 0.15 to 0.6% by volume of halothane.
Die kombinierte Verwendung von Xenon und einem volatilen Anästhesiemittel bringt große Vorteile bei der Anästhesie gegenüber der Verwendung des einzelnen Anästhesiemittels. Bei dem Kombinationsinhalationsanästhesiemittel ist ein Sauerstoffgehalt im Beatmungsgas von mehr als 29 Vol.-% möglich (MAC von Xenon bei 71 % beim Menschen). Kritische Operationen, die eine höhere Sauerstoffzufuhr bei der Beatmung des Menschen erfordern, sind daher möglich, wobei die Vorteile bei der Verabreichung von Xenon weitgehend genutzt werden. Die volatilen Anästhesiemittel werden in solchen Mengen einsetzbar, wo die Nebenwirkungen der volatilen Anästhesiemittel nicht mehr in dem bekannten Maße auftreten. Insbesondere erhält der Anästhesist bei dem Kombinationsanästhesiemittel eine höhere Flexibilität in der Steuerung einer Narkose. Überraschenderweise läßt sich durch Verabreichung von Xenon die in der Regel mehr oder weniger ausgeprägte Absenkung des Blutdruckes bei der Anästhesie gegensteuern und sogar weitgehend kompensieren. Durch gezielte Dosierung von Xenon in das Atemgas wird bei Einsatz eines volatilen Anästhesiemittels eine möglicherweise gefährliche Blutdrucksenkung verhindert.The combined use of xenon and a volatile anesthetic brings great benefits in anesthesia over the use of the single anesthetic. In the combination inhalation anesthetic, an oxygen content in the breathing gas of more than 29% by volume is possible (MAC of xenon at 71% in humans). Critical operations requiring higher oxygenation in human respiration are therefore possible, and the benefits of administering xenon are widely exploited. The volatile anesthetics are used in such quantities where the side effects of volatile anesthetic are no longer present in the known dimensions occur. In particular, the anesthetist in the combination anesthetic is given greater flexibility in controlling anesthesia. Surprisingly, by administering xenon, the usually more or less marked lowering of the blood pressure during anesthesia can be counteracted and even largely compensated. Targeted dosing of xenon into the respiratory gas prevents a potentially dangerous lowering of blood pressure when using a volatile anesthetic.
Beispielsweise gibt es einen additiven anästhetischen Effekt von inhaliertem Xenon und Isofluran, der es dem Anästhesisten erlaubt, die Anästhesie mit Xenon in einer schnellen, einfachen und billigen Weise zu ergänzen, wenn ein höherer Sauerstoffbedarf des Patienten besteht. Z.B. bei einem FiO2 0,5 ergibt sich eine Xenon-Konzentration von 50 Vol.-%, der MAC von Isofluran wird um etwa 30 % gesenkt. Dies erlaubt eine Senkung der Isofluran-Dosis, was die Nebenwirkungen reduziert und zu einer sichereren Anästhesietechnik führt. Die kombinierte Dosierung von Xenon und einem volatilen Anästhesiemittel zur Anästhesie ist besonders vorteilhaft bei Patienten mit kardiopulmonalen Erkrankungen und bei Operationen mit zu erwartendem hohen Blutverlust.For example, there is an additive anesthetic effect of inhaled xenon and isoflurane that allows the anesthesiologist to supplement anesthesia with xenon in a quick, easy, and inexpensive manner when there is a higher oxygen demand of the patient. For example, with a FiO 2 0.5 results in a xenon concentration of 50 vol .-%, the MAC of isoflurane is reduced by about 30%. This allows a reduction in the dose of isoflurane, which reduces the side effects and leads to a safer anesthetic technique. The combined dosage of xenon and a volatile anesthetic for anesthesia is particularly beneficial in patients with cardiopulmonary disease and in operations with expected high blood loss.
Das eingesetzte Xenon-Gas hat im allgemeinen die natürliche lsotopenzusammensetzung. Die Isotopenzusammensetzung des Xenons kann sich von der natürlichen Isotopenzusammensetzung unterscheiden.The xenon gas used generally has the natural isotopic composition. The isotopic composition of xenon may differ from the natural isotopic composition.
Das Xenon-Gas wird vorzugsweise in hoher Reinheit, wie für medizinische Gase üblich, eingesetzt. Das Xenon-Gas dient als reines Gas oder im Gemisch mit anderen Gasen als Komponente von einem Kombinationsinhalationsanästhesiemittel oder Kombinationsinhalationsnarkosemittel zur gleichzeitigen, getrennten oder zeitlich abgestuften Anwendung mit den anderen Anästhesiemittelkomponenten bei der Anästhesie.The xenon gas is preferably used in high purity as usual for medical gases. The xenon gas serves as a pure gas or in admixture with other gases as a component of a combination inhalation anesthetic or combination inhalation anesthetic for simultaneous, separate or sequential use with the other anesthetic components in anesthesia.
Gasförmiges Xenon wird im allgemeinen als komprimiertes, reines Gas in Druckgasbehältem wie Druckgasflaschen oder Druckdosen bereitgestellt. Xenon kann auch in einem Behälter als verflüssigtes Gas oder in kälteverfestigter Form bereitgestellt werden. Volatile Anästhesiemittel werden im allgemeinen als Flüssigkeiten bereitgestellt.Gaseous xenon is generally provided as compressed, clean gas in pressurized gas containers such as compressed gas cylinders or pressure cans. Xenon can be provided in a container as a liquefied gas or in cold-strengthened form. Volatile anesthetics are generally provided as liquids.
Volatile Anästhesiemittel und Xenon werden als Kombinationsanästhesiemittel beispielsweise mit Minimal flow-Anästhesiegeräten oder sogenannten Closed loop-Anästhesiegeräten, z.B. mit dem Gerät "Physioflex" von der Firma Dräger (Lübeck, Deutschland), verabreicht.Volatile anesthetics and xenon are used as combination anesthetic agents, for example, with minimal flow anesthesia machines or so-called closed loop anesthesia machines, e.g. with the device "Physioflex" from Dräger (Lübeck, Germany) administered.
Nach Genehmigung der zuständigen Tierschutzbehörde (Bez.-Regierung Köln, AZ: 23.203.2-AC 38, 27/99) wurde die Bestimmung des MAC-Wertes an 10 weiblichen Schweinen einer deutschen Landrasse mit einem Gewicht vom 28,6 - 35,8 kg (im Mittel 31,5 kg) bestimmt. Bei Aufnahme der Versuchstiere in das Institut für Versuchstierkunde der RWTH Aachen wurden alle Tiere von Tierärzten des Instituts eingehend untersucht. Diese Untersuchung umfaßte unter anderem das Verhalten des Tieres, die Körperhaltung, Gliedmaßen, Haut und Haare und die Schleimhäute. Herz und Lungen wurden auskultiert. Bei keinem Tier zeigten sich krankheitsbedingte Veränderungen. Die Körpertemperatur der Tiere lag nach Aufnahme zwischen 37,2 und 39,2 °C (im Mittel bei 38,2°C). Nach einer Überwachungsperiode von mindestens fünf Tagen und Ernährung mit einer Standardtiemahrung für Schweine, wurden die Tiere in den Versuch gebracht.After approval of the competent animal protection authority (Bez.-Government Cologne, AZ: 23.203.2-AC 38, 27/99), the determination of the MAC value on 10 female pigs of a German Landrace weighing 28.6-35.8 kg (average 31.5 kg). When the test animals were admitted to the Institute for Experimental Animal Science of the RWTH Aachen, all animals were examined in detail by veterinarians of the institute. This study included, among other things, the behavior of the animal, posture, limbs, skin and hair, and mucous membranes. Heart and lungs were auscultated. No animal showed disease-related changes. The body temperature of the animals was between 37.2 and 39.2 ° C after admission (mean 38.2 ° C). After a monitoring period of at least five days and diet with a standard pig diet, the animals were tested.
Nach einer Prämedikation von 3 mg/kg Azerperon i.m. (intramuskulös) wurde 20 min. später eine Venenverweilkanüle in eine Ohrvene gelegt. Die Einleitung der Narkose erfolgte mit Propofol in 2 mg/kg KG. Die Intubation erfolgte ohne Muskelrelaxanz mit einem 7.5 mm Woodbridge-Tubus. Im weiteren Verlauf wurde eine arterielle Kanüle percutan in die Ohrarterie zur blutigen Blutdruckmessung und div. Blutabnahmen gelegt. Die Narkose wurde in dieser Phase mit Boli von 20 mg/kg KG Propofol fortgesetzt. Die kumulativen Dosen lagen zwischen 170 und 500 mg (im Mittel 276 mg).
Die Tiere wurden kontrolliert beatmet, so daß das exspiratorische CO2 kontinuierlich zwischen 40-45 mmHg lag. Alle Tiere wurden mit einem Inspirations/Exspirationsverhältnis von 1:1 und einem positiv end-exspiratorischen Druck (PEEP) von +3 cmH2O beatmet. Als Narkosegerät diente ein Dräger PhysioFlex. Die Köpertemperatur wurde mittels einer Heizdecke (warm-touch, Mallinckrodt Medical, Ireland) auf einer Temperatur zwischen 38,0 °C und 39,5 °C konstantgehalten. Kontinuierlich wurden MAP (mittlerer arterieller Druck; mean arterial blood pressure), HR (Herzfrequenz; heart rate), Temperatur gemonitort (AS/3 compact, Datex-Engström, Heisinki/Finnland). Bei Applikation des supramaximalen Stimulus wurden die jeweils aktuellen Werte notiert. Die in- und exspiratorische Konzentration des Halothans wurde mittels Infrarot Spektroskopie (AS/3 compact, Datex-Engström, Helsinki, Finnland) die inspiratorische Xenon-Konzentration wurde mittels Infrarot Spektroskopie mit mit Hilfe des PhysioFlex (Physio ä Dräger company, Lübeck Germany) gemonitort. Aufgrund der pharmacokinetischen Eigenschaften des Edelgases Xenon, ist von einer sehr raschen Äquilibration zwischen inspirations- und exspirations Konzentration auszugehen, so daß bei einer standardmäßigen Äquilibierungszeit von 20 min. davon ausgegangen darf, daß die inspirations- und exspirations Konzentration identisch ist.
Bei jeder Messung wurden PaO2 (Partialdruck von Sauerstoff; tension in arterial blood), PaCO2 (Partialdruck von Kohlendioxid; carbondioxid tension in arterial blood), pH-Wert, Natrium und Kalium mittels eines Blutgasanalysators (ABL 500 + EML 100, Radiometer Copenhagen, Danmark) bestimmt.
Die Harnblase wurde katheterisiert. Mit Beginn der Katheterisierung wurde bis zum Ende des Versuchs eine kontinuierliche Infusion einer Elektrolytlösung von 0,1 ml/kg KG/min begonnen. Nach Beendigung der Präparation wurde die Narkose mit Halothan solange fortgeführt, bis die Propofolwirkung keinen Einfluß auf den MAC-Wert hatte. Zur Bestimmung des Zeitpunkts dienten die Berechnungen nach Cockshott et al. und Adams et al., die beide zeigen konnten, daß die Propofol-But-Konzentration bei Boli-Gaben von 2-5 mg/kg KG (KG: Körpergewicht) nach 45 min auf unter 10 % der Ausgangskonzentration abgesunken war.After a premedication of 3 mg / kg Azerperon im (intramuscular) was 20 min. later a venous indwelling cannula placed in an ear vein. The induction of anesthesia took place with propofol in 2 mg / kg body weight. Intubation was performed without muscle relaxation using a 7.5 mm Woodbridge tube. In the further course, an arterial cannula was placed percutaneously in the artery of the ear for bloody blood pressure measurement and various blood collections. The anesthesia continued in this phase with boluses of 20 mg / kg bw propofol. The cumulative doses were between 170 and 500 mg (mean 276 mg).
The animals were ventilated in a controlled manner so that the expiratory CO 2 was continuously between 40-45 mmHg. All animals were ventilated with an inspiratory / expiratory ratio of 1: 1 and a positive end-expiratory pressure (PEEP) of +3 cmH 2 O. The anesthesia device was a Dräger PhysioFlex. The body temperature was kept constant by means of a heating blanket (warm-touch, Mallinckrodt Medical, Ireland) at a temperature between 38.0 ° C and 39.5 ° C. MAP (mean arterial blood pressure), HR (heart rate), temperature were monitored continuously (AS / 3 compact, Datex-Engström, Heisinki / Finland). When applying the supramaximal stimulus, the current values were noted. The inhalation and expiratory concentration of halothane was monitored by infrared spectroscopy (AS / 3compact, Datex-Engstrom, Helsinki, Finland). The inspiratory xenon concentration was monitored by means of infrared spectroscopy using the PhysioFlex (Physio ä Dräger company, Lübeck Germany) , Due to the pharmacokinetic properties of the noble gas xenon, a very rapid equilibrium between inspiratory and expiratory concentration can be assumed, so that with a standard equilibration time of 20 min. It may be assumed that the concentration of inspiration and exhalation is identical.
For each measurement, PaO 2 (partial pressure of oxygen, tension in arterial blood), PaCO 2 (partial pressure of carbon dioxide, arterial blood), pH, sodium and potassium were measured by a blood gas analyzer (ABL 500 + EML 100, Radiometer Copenhagen , Danmark).
The urinary bladder was catheterized. At the beginning of the catheterization, a continuous infusion of an electrolyte solution of 0.1 ml / kg bw / min was started until the end of the experiment. After completion of the preparation, anesthesia with halothane was continued until the propofol effect had no effect on the MAC value. In order to determine the time, the calculations according to Cockshott et al. and Adams et al., both of whom were able to demonstrate that the propofol-but concentration was 2-5 in bolus doses mg / kg body weight (body weight: KG) had fallen to below 10% of the initial concentration after 45 min.
Zur Bestimmung der MAC-Werte von Halothan in 0, 15, 30, 40, 50 und 65 Vol.-% Xenon wurde die Konzentration des Halothans in Schritten um 0,1 Vol. % erhöht bzw. erniedrigt. Die 10 Tiere wurden randomisiert den je zwei Versuchsgruppen zugeteilt. Gruppe 1 begann mit Xenon 0 Vol.-% und absteigenden Konzentrationen des Halothans. Die 2. Gruppe begann mit Xenon 65 Vol.-% und aufsteigenden Konzentrationen. Generell wurde frühstens 3 Stunden nach Prämedikation und 1 Stunde nach der letzten Propofol-Gabe mit dem Versuchsprotokoll begonnen. Hierdurch ließen sich Einflüsse der Prämedikation und der Propofolgaben ausschließen. Bis zum nächsten Messzeitpunkt wurde eine Äquilibrierungszeit von mindestens 15 min. eingehalten und abgewartet bis sich steadystate-Bedingungen eingestellt hatten. Die Messungen wurden solange durchgeführt, bis eine Änderung der Reaktion auf den Schmerzreiz zu verzeichnen war.To determine the MAC values of halothane in 0, 15, 30, 40, 50 and 65% by volume of xenon, the concentration of halothane was increased or decreased in steps of 0.1% by volume. The 10 animals were randomized to the two experimental groups. Group 1 started with xenon 0 vol% and descending halothane concentrations. The second group started with xenon 65% by volume and increasing concentrations. In general, the trial protocol was started at the earliest 3 hours after premedication and 1 hour after the last propofol administration. As a result, influences of premedication and propofol administration could be ruled out. Until the next measurement time, an equilibration time of at least 15 min. maintained and waited until steady state conditions had set. The measurements were carried out until a change in the response to the pain stimulus was recorded.
Ein supramaximaler Schmerzstimulus wurde nach der dew-claw-clamp Methode von Eger et al. (1988) durchgeführt.A supramaximal pain stimulus was determined by the dew-claw-clamp method of Eger et al. (1988).
Die Ergebnisse der einzelnen Xenon-Konzentrationen sind in Tab. 6 dargestellt.
Während des gesamten Versuchsablaufs wurden die gemonitorten Parameter möglichst konstant gehalten. Es zeigen sich zwischen den unterschiedlichen Xenon-Konzentrationen keine signifikanten Unterschiede. Einzig der PaO2 veränderte sich entsprechend des FiO2 (fractional inspired oxygen tension). Durch Bestimmung des PaO2/ FiO2 Indexes lassen sich die Werte jedoch gut miteinander Vergleichen (s. Tab. 7 und 8).
Die Versuche mit lsofluran-Xenon am Schwein wurden analog zu Beispiel 1 durchgeführt.The experiments with lsoflurane xenon in pigs were carried out analogously to Example 1.
Die Ergebnisse sind in den folgenden Tabellen zusammengestellt.
Claims (9)
- Anaesthetic comprising xenon or a xenon-comprising gas and a volatile anaesthetic as combination product for simultaneous, separate or sequential application in anaesthesia, the volatile anaesthetic being isoflurane, sevoflurane or desflurane.
- Anaesthetic according to Claim 1, characterized in that xenon is used in a concentration in the range of 10 to 80% by volume.
- Anaesthetic according to Claim 1 or 2,
characterized in that the volatile anaesthetic is isoflurane, sevoflurane or desflurane and is used in the concentration range of 0.5 to 1.15% by volume of isoflurane, 0.9 to 2.0% by volume of sevoflurane, and 3.6 to 6.0% by volume of desflurane. - Gas mixture for anaesthesia, composed of 10 to 65% by volume of xenon, a volatile anaesthetic and oxygen, the proportions of xenon, volatile anaesthetic and oxygen together giving 100% by volume, and the volatile anaesthetic being isoflurane, sevoflurane or desflurane.
- Gas mixture according to Claim 4, characterized in that the proportion of xenon and volatile anaesthetic is chosen such that the patient's blood pressure is not substantially changed.
- Gas mixture according to Claim 4 or 5,
characterized in that the proportion of oxygen is at least 30% by volume. - Gas mixture for anaesthesia, composed of 10 to 65% by volume of xenon, a volatile anaesthetic, oxygen and one or more inert gases, the proportions of all the components of the gas mixture together giving 100% by volume, the volatile anaesthetic being isoflurane, sevoflurane or desflurane and being used in the concentration range of 0.5 to 1.15% by volume of isoflurane, 0.9 to 2.0% by volume of sevoflurane, and 3.6 to 6.0% by volume of desflurane.
- Use of xenon and of a volatile anaesthetic for producing a combination anaesthetic for separate or sequential application of the components in anaesthesia.
- Use of xenon and of a volatile anaesthetic for producing a combination anaesthetic for simultaneous, separate or sequential application of the components in anaesthesia of patients with cardiopulmonary diseases or in operations involving substantial loss of blood.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07024046A EP1908458B1 (en) | 2000-09-14 | 2001-09-10 | Volatile anaesthetic with xenon |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10045829 | 2000-09-14 | ||
DE10045829A DE10045829A1 (en) | 2000-09-14 | 2000-09-14 | Volatile anesthetic with xenon |
PCT/EP2001/010401 WO2002022116A1 (en) | 2000-09-14 | 2001-09-10 | Volatile anaesthetic with xenon |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07024046A Division EP1908458B1 (en) | 2000-09-14 | 2001-09-10 | Volatile anaesthetic with xenon |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1318797A1 EP1318797A1 (en) | 2003-06-18 |
EP1318797B1 true EP1318797B1 (en) | 2008-01-09 |
Family
ID=7656432
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07024046A Expired - Lifetime EP1908458B1 (en) | 2000-09-14 | 2001-09-10 | Volatile anaesthetic with xenon |
EP01965268A Expired - Lifetime EP1318797B1 (en) | 2000-09-14 | 2001-09-10 | Volatile anaesthetic with xenon |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07024046A Expired - Lifetime EP1908458B1 (en) | 2000-09-14 | 2001-09-10 | Volatile anaesthetic with xenon |
Country Status (8)
Country | Link |
---|---|
EP (2) | EP1908458B1 (en) |
AT (2) | ATE501714T1 (en) |
AU (1) | AU2001285939A1 (en) |
DE (3) | DE10045829A1 (en) |
DK (1) | DK1318797T3 (en) |
ES (2) | ES2299509T3 (en) |
PT (1) | PT1318797E (en) |
WO (1) | WO2002022116A1 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7235264B2 (en) | 2002-06-12 | 2007-06-26 | Air Liquide Deutschland Gmbh | Cerebral protection with a gas comprising xenon |
AU2003249959A1 (en) * | 2002-07-05 | 2004-01-23 | Messer Griesheim Gmbh | Adjuvant containing xenon |
DE10329908A1 (en) * | 2003-07-02 | 2005-02-03 | Messer Griesheim Gmbh | Composition comprising xenon and local anesthetic, useful in regional or local anesthetic procedures |
GB0418540D0 (en) * | 2004-08-19 | 2004-09-22 | Protexeon Ltd | Use |
FR2894486B1 (en) | 2005-12-14 | 2008-11-21 | Air Liquide | XENON CONCENTRATION MEASUREMENT DEVICE AND XENON VENTILATORY ANESTHESIA APPARATUS |
FR2931682B1 (en) | 2008-05-27 | 2010-07-30 | Air Liquide | IMPROVING THE PRECISION FOR MEASURING XENON CONTENT IN A VENTILATORY ANESTHESIA APPARATUS. |
WO2010025505A1 (en) * | 2008-09-04 | 2010-03-11 | Phebra Pty Ltd | Analgesia by transmucosal administration |
WO2010040656A1 (en) | 2008-10-06 | 2010-04-15 | L'air Liquide Societe Anonyme Pour L'etude Et L'exploitation Des Procedes Georges Claude | Xenon-based gaseous anaesthetic to be administered via a heart lung machine |
RU2532015C1 (en) * | 2013-11-19 | 2014-10-27 | Государственное бюджетное образовательное учреждение дополнительного профессионального образования "Новокузнецкий государственный институт усовершенстовования врачей" Министерства здравоохранения Российской Федерации | Method for anaesthesia accompanying adenotomy and tonsillotomy in children |
RU2703686C1 (en) * | 2018-05-08 | 2019-10-21 | Общество С Ограниченной Ответственностью "Владимед" | Method of general anesthesia with preserved spontaneous breathing for medium- and low-traumatic surgical operations |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1499819A (en) * | 1975-04-29 | 1978-02-01 | Ici Ltd | Anaesthetic compositions |
US5099834A (en) * | 1991-07-16 | 1992-03-31 | Union Carbide Industrial Gases Technology Corporation | Method for anesthesia |
GB2304468B (en) * | 1995-08-21 | 1997-08-06 | Otter Controls Ltd | Improvements relating to thermal controls |
DE19833014A1 (en) * | 1998-07-23 | 2000-01-27 | Messer Griesheim Gmbh | Injectable anesthetic comprising noble gas(es) in gaseous form, also showing analgesic, sedative, antiinflammatory and muscle relaxant actions |
DE19851604A1 (en) * | 1998-11-09 | 2000-05-11 | Messer Griesheim Gmbh | Injection anesthetic with a hydrophilic phase |
DE19910986C2 (en) * | 1999-03-11 | 2001-06-07 | Aga Ab | Use of xenon in the treatment of neurointoxication |
-
2000
- 2000-09-14 DE DE10045829A patent/DE10045829A1/en not_active Ceased
-
2001
- 2001-09-10 DK DK01965268T patent/DK1318797T3/en active
- 2001-09-10 EP EP07024046A patent/EP1908458B1/en not_active Expired - Lifetime
- 2001-09-10 PT PT01965268T patent/PT1318797E/en unknown
- 2001-09-10 AT AT07024046T patent/ATE501714T1/en active
- 2001-09-10 ES ES01965268T patent/ES2299509T3/en not_active Expired - Lifetime
- 2001-09-10 AU AU2001285939A patent/AU2001285939A1/en not_active Abandoned
- 2001-09-10 DE DE50115823T patent/DE50115823D1/en not_active Expired - Lifetime
- 2001-09-10 AT AT01965268T patent/ATE383151T1/en not_active IP Right Cessation
- 2001-09-10 ES ES07024046T patent/ES2362932T3/en not_active Expired - Lifetime
- 2001-09-10 WO PCT/EP2001/010401 patent/WO2002022116A1/en active IP Right Grant
- 2001-09-10 DE DE50113480T patent/DE50113480D1/en not_active Expired - Lifetime
- 2001-09-10 EP EP01965268A patent/EP1318797B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
PT1318797E (en) | 2008-04-15 |
EP1908458A1 (en) | 2008-04-09 |
EP1908458B1 (en) | 2011-03-16 |
DE10045829A1 (en) | 2002-04-04 |
ATE501714T1 (en) | 2011-04-15 |
ES2299509T3 (en) | 2008-06-01 |
DE50115823D1 (en) | 2011-04-28 |
DE50113480D1 (en) | 2008-02-21 |
DK1318797T3 (en) | 2008-05-26 |
WO2002022116A1 (en) | 2002-03-21 |
ATE383151T1 (en) | 2008-01-15 |
ES2362932T3 (en) | 2011-07-15 |
EP1318797A1 (en) | 2003-06-18 |
AU2001285939A1 (en) | 2002-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Drummond et al. | Arterial oxygen saturation before intubation of the trachea: An assessment of oxygenation techniques | |
Tsai et al. | Recovery of cognitive functions after anaesthesia with desflurane or isoflurane and nitrous oxide | |
DE69725759T2 (en) | DEVICE FOR REMOVING ANESTHETIC VAPOR FROM A PATIENT AFTER SURGICAL OPERATION | |
Yurino et al. | A comparison of vital capacity breath and tidal breathing techniques for induction of anaesthesia with high sevoflurane concentrations in nitrous oxide and oxygen | |
US5099834A (en) | Method for anesthesia | |
US5228434A (en) | Mixture for anesthesia | |
GOZALO‐MARCILLA et al. | Effects of a constant‐rate infusion of dexmedetomidine on the minimal alveolar concentration of sevoflurane in ponies | |
Hubbell et al. | Effect of 50% and maximal inspired oxygen concentrations on respiratory variables in isoflurane-anesthetized horses | |
EP1318797B1 (en) | Volatile anaesthetic with xenon | |
Hopster et al. | Controlled mechanical ventilation with constant positive end-expiratory pressure and alveolar recruitment manoeuvres during anaesthesia in laterally or dorsally recumbent horses | |
Yurino et al. | Comparison of induction time and characteristics between sevoflurane and sevoflurane/nitrous oxide | |
Moens et al. | Influence of tidal volume and positive end-expiratory pressure on inspiratory gas distribution and gas exchange during mechanical ventilation in horses positioned in lateral recumbency | |
EP1318820B1 (en) | Medicament containing sub-anesthetic concentrations of xenon for use in the treatment of cardiovascular diseases | |
Flecknell et al. | Halothane anaesthesia in the rabbit: a comparison of the effects of medetomidine, acepromazine and midazolam on breath-holding during induction | |
Cole et al. | Blood oxygen saturation during anaesthesia with volatile agents vaporized in room air | |
Davis et al. | Determination of the minimum alveolar concentration (MAC) of halothane in the white New Zealand rabbit | |
Philip et al. | Vital capacity induction with sevoflurane in adult surgical patients | |
Butler | Pharmacokinetics of halothane and ether | |
Nyman et al. | Comparison of conventional and selective mechanical ventilation in the anaesthetized horse; effects on central circulation and pulmonary gas exchange | |
Rowbottom et al. | Comparison of conventional and rapid inhalational induction of anaesthesia with enflurane | |
CA1060799A (en) | Anaesthetic compositions | |
DE69128780T2 (en) | USE OF ADENOSINE AND ADENOSINE DERIVATIVES FOR ANESTHESIA | |
Santos et al. | Cardiopulmonary effects of desflurane in horses | |
Söderberg et al. | A clinical trial of enflurane in children | |
Eriksson et al. | The influence of 0.5% isoflurane on a vecuronium‐induced neuromuscular blockade |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20030414 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: HECKER, KLAUS Inventor name: SCHUCHT, FRIDTJOF Inventor name: PILGER, CARSTEN Inventor name: BAUMERT, JAN-HINRICH Inventor name: HORN, NICOLA Inventor name: COPPIN, ARNOLD Inventor name: NEU, PETER Inventor name: ROSSAINT, ROLF Inventor name: THOMA, KLEMENS Inventor name: REYLE-HAHN, MATTHIAS |
|
17Q | First examination report despatched |
Effective date: 20040129 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: AIR LIQUIDE DEUTSCHLAND GMBH |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: AIR LIQUIDE DEUTSCHLAND GMBH |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: AIR LIQUIDE DEUTSCHLAND GMBH |
|
17Q | First examination report despatched |
Effective date: 20040129 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 23/00 20060101ALI20070716BHEP Ipc: A61K 31/02 20060101AFI20070716BHEP |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D Free format text: NOT ENGLISH |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D Free format text: LANGUAGE OF EP DOCUMENT: GERMAN |
|
RIN2 | Information on inventor provided after grant (corrected) |
Inventor name: HECKER, KLAUS Inventor name: PILGER, CARSTEN Inventor name: NEU, PETER Inventor name: SCHUCHT, FRIDTJOF Inventor name: ROSSAINT, ROLF Inventor name: REYLE-HAHN, MATTHIAS Inventor name: THOMA, KLEMENS Inventor name: BAUMERT, JAN-HINRICH Inventor name: HORN, NICOLA Inventor name: COPPING, ARNOLD |
|
REF | Corresponds to: |
Ref document number: 50113480 Country of ref document: DE Date of ref document: 20080221 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20080403 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
GBT | Gb: translation of ep patent filed (gb section 77(6)(a)/1977) |
Effective date: 20080417 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20080400993 Country of ref document: GR |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2299509 Country of ref document: ES Kind code of ref document: T3 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080109 |
|
ET | Fr: translation filed | ||
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FD4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080109 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20080815 Year of fee payment: 8 Ref country code: LU Payment date: 20080912 Year of fee payment: 8 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20080813 Year of fee payment: 8 Ref country code: MC Payment date: 20080821 Year of fee payment: 8 |
|
26N | No opposition filed |
Effective date: 20081010 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080109 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090930 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090910 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080109 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090930 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090930 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090910 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DK Payment date: 20110926 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20120919 Year of fee payment: 12 Ref country code: GB Payment date: 20120920 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GR Payment date: 20120926 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20120919 Year of fee payment: 12 Ref country code: DE Payment date: 20120921 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: PT Payment date: 20120312 Year of fee payment: 12 Ref country code: NL Payment date: 20120920 Year of fee payment: 12 Ref country code: FR Payment date: 20121010 Year of fee payment: 12 Ref country code: BE Payment date: 20120920 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20120927 Year of fee payment: 12 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: MM4A Free format text: LAPSE DUE TO NON-PAYMENT OF FEES Effective date: 20140310 |
|
BERE | Be: lapsed |
Owner name: AIR LIQUIDE DEUTSCHLAND G.M.B.H. Effective date: 20130930 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: V1 Effective date: 20140401 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: EUG |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130911 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP Effective date: 20130930 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: ML Ref document number: 20080400993 Country of ref document: GR Effective date: 20140403 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20130910 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 50113480 Country of ref document: DE Effective date: 20140401 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20140530 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140310 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130910 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130930 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130910 Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140403 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130930 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140401 Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140401 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20141008 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130930 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130911 |